Background The exhaustive information about non-communicable diseases associated with COVID-19 and severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) are getting easier to find in the literature. However, there is a lack of knowledge regarding tuberculosis (TB) and chronic obstructed pulmonary disease (COPD), with numerous infections in COVID-19 patients. Objectives Priority is placed on determining the patient’s prognosis based on the presence or absence of TB and COPD. Additionally, a comparison is made between the risk of death and the likelihood of recovery in terms of time in COVID-19 patients who have either COPD or TB. Methodology At the DHQ Hospital in Muzaffargarh, Punjab, Pakistan, 498 COVID-19 patients with TB and COPD were studied retrospectively. The duration of study started in February 2022 and concluded in August 2022. The Kaplan–Meier curves described time-to-death and time-to-recovery stratified by TB and COPD status. The Wilcoxon test compared the survival rates of people with TB and COPD in two matched paired groups and their status differences with their standard of living. Results The risk of death in COVID-19 patients with TB was 1.476 times higher than in those without (95% CI: 0.949–2.295). The recovery risk in COVID-19 patients with TB was 0.677 times lower than in those without (95% CI: 0.436–1.054). Similarly, patients with TB had a significantly shorter time to death ( p =.001) and longer time to recovery ( p =.001). Conclusions According to the findings, the most significant contributor to an increased risk of morbidity and mortality in TB and COPD patients was the COVID-19. KEY MESSAGES SARS-Cov-19 is a new challenge for the universe in terms of prevention and treatment for people with tuberculosis and chronic obstructive pulmonary disease, among other diseases. Propensity score matching to control for potential biases. Compared to hospitalized patients with and without (TB and COPD) had an equivalently higher mortality rate.

No abstract

No abstract

For $p\geq 2$, let $E$ be a 2-uniformly smooth and $p$-uniformly convex real Banach space and let $A:E\rightarrow E^{\ast }$ be a Lipschitz and strongly monotone mapping such that $A^{-1}(0)\neq \emptyset$. For given $x_{1}\in E$, let $\{x_{n}\}$ be generated by the algorithm $x_{n+1}=J^{-1}(Jx_{n}-\unicode[STIX]{x1D706}Ax_{n})$, $n\geq 1$, where $J$ is the normalized duality mapping from $E$ into $E^{\ast }$ and $\unicode[STIX]{x1D706}$ is a positive real number in $(0,1)$ satisfying suitable conditions. Then it is proved that $\{x_{n}\}$ converges strongly to the unique point $x^{\ast }\in A^{-1}(0)$. Furthermore, our theorems provide an affirmative answer to the Chidume et al. open problem [‘Krasnoselskii-type algorithm for zeros of strongly monotone Lipschitz maps in classical Banach spaces’, SpringerPlus4 (2015), 297]. Finally, applications to convex minimization problems are given.

In the present study, the group acceptance plan is examined when the lifetime of an item follows the odd Perks exponential distribution, and a large number of items regarded as a group are evaluated simultaneously. The crucial parameters are derived from the consumer risk and the test termination period. The operating characteristics function values are generated for various quality levels. An optimized group acceptance plan and comparison of group acceptance sampling plan with the ordinary sampling plan are also presented. Additionally, a graphical illustration of operating characteristics for diverse groups and parametric values is provided. The minimum ratios of the actual average life to the stipulated average life are likewise computed at the prescribed producer’s risk. Examples are used to illustrate the outcomes via our algorithm under the odd Perks exponential distribution setting. It is explained using a quality control dataset to establish its practical versatility.